Robert Driscoll
Stock Analyst at Wedbush
(3.23)
# 1,085
Out of 5,182 analysts
175
Total ratings
41.29%
Success rate
3.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Outperform | $37 → $41 | $22.34 | +83.53% | 8 | Apr 2, 2026 | |
| EIKN Eikon Therapeutics | Reiterates: Underperform | $7 | $9.00 | -22.22% | 2 | Mar 31, 2026 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $30.50 | +70.49% | 11 | Mar 31, 2026 | |
| APRE Aprea Therapeutics | Reiterates: Outperform | $7 | $0.92 | +663.53% | 5 | Mar 31, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Outperform | $13 → $14 | $2.56 | +446.88% | 11 | Mar 17, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Outperform | $6 → $11 | $4.39 | +150.57% | 10 | Mar 17, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Outperform | $10 | $4.59 | +117.86% | 8 | Mar 12, 2026 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $34 → $36 | $14.54 | +147.59% | 6 | Mar 11, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Neutral | $30 → $22 | $21.47 | +0.14% | 8 | Mar 9, 2026 | |
| KURA Kura Oncology | Maintains: Outperform | $38 → $36 | $8.67 | +315.22% | 12 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $19 | $19.95 | -4.76% | 5 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $11 | $10.82 | +1.66% | 10 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $53 | $35.26 | +50.31% | 10 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $4.76 | +299.16% | 8 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $147 | $96.43 | +52.44% | 9 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $67.70 | +3.40% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $9.80 | +287.76% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $18.17 | +48.60% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $6.61 | -39.49% | 11 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $6 | $0.85 | +606.71% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $17.48 | -2.75% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $6.76 | +1,083.43% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $14.93 | +395.65% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.17 | +54.74% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.67 | +319.16% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.15 | -3.61% | 4 | May 19, 2020 |
Arcus Biosciences
Apr 2, 2026
Maintains: Outperform
Price Target: $37 → $41
Current: $22.34
Upside: +83.53%
Eikon Therapeutics
Mar 31, 2026
Reiterates: Underperform
Price Target: $7
Current: $9.00
Upside: -22.22%
IDEAYA Biosciences
Mar 31, 2026
Reiterates: Outperform
Price Target: $52
Current: $30.50
Upside: +70.49%
Aprea Therapeutics
Mar 31, 2026
Reiterates: Outperform
Price Target: $7
Current: $0.92
Upside: +663.53%
Black Diamond Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $2.56
Upside: +446.88%
CytomX Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $6 → $11
Current: $4.39
Upside: +150.57%
Foghorn Therapeutics
Mar 12, 2026
Reiterates: Outperform
Price Target: $10
Current: $4.59
Upside: +117.86%
Cullinan Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $34 → $36
Current: $14.54
Upside: +147.59%
Day One Biopharmaceuticals
Mar 9, 2026
Downgrades: Neutral
Price Target: $30 → $22
Current: $21.47
Upside: +0.14%
Kura Oncology
Mar 6, 2026
Maintains: Outperform
Price Target: $38 → $36
Current: $8.67
Upside: +315.22%
Mar 6, 2026
Maintains: Outperform
Price Target: $15 → $19
Current: $19.95
Upside: -4.76%
Feb 25, 2026
Maintains: Neutral
Price Target: $9 → $11
Current: $10.82
Upside: +1.66%
Feb 13, 2026
Maintains: Outperform
Price Target: $37 → $53
Current: $35.26
Upside: +50.31%
Feb 4, 2026
Maintains: Outperform
Price Target: $18 → $19
Current: $4.76
Upside: +299.16%
Jan 9, 2026
Maintains: Outperform
Price Target: $80 → $147
Current: $96.43
Upside: +52.44%
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $67.70
Upside: +3.40%
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $9.80
Upside: +287.76%
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $18.17
Upside: +48.60%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $6.61
Upside: -39.49%
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.85
Upside: +606.71%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $17.48
Upside: -2.75%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $6.76
Upside: +1,083.43%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $14.93
Upside: +395.65%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.17
Upside: +54.74%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.67
Upside: +319.16%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.15
Upside: -3.61%